Home › Research › Treatments
Characterization of the Anti-Alzheimer Drug Lecanemab by Mass Spectrometry
Jiaojiao Sha, Zijin Geng, Shanyu Qi, Liangjia Du, Qianqian Hu, Minqi Cai, Dezhu Chen, Yuehua Chen et al.. ACS Omega, 2026-06-08
Topic: Amyloid, tau and blood-test diagnosis
-glycans found at the N304 site of lecanemab of the heavy chain. Further analysis by MSFragger identified other modifications and additional glycosites. These results provide data as resource for the identification of critical quality attributes of lecanemab in studying its therapeutic effectiveness, side effects, and possible batch-to-batch qualities.
Key findings
- These results provide data as resource for the identification of critical quality attributes of lecanemab in studying its therapeutic effectiveness, side effects, and possible batch-to-batch qualities.
Why it matters
This laboratory analysis characterised lecanemab's structure and modifications by mass spectrometry. It provides data as a resource for identifying critical quality attributes of lecanemab, not evidence that the drug treats, cures or prevents Alzheimer disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 35 of the 96 points we could judge it on, which is 36 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (ACS Omega) |
| Journal's citation record | 2 / 4 | ACS Omega: journal h-index 178 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Bing Bai holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 1 / 3 | Tsinghua University: institution h-index 1,218 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42368154) |
| Free to read | 2 / 2 | Free to read |
| Points | 35 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 35 of the 96 points we could judge it on is 36 out of 100. |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Sha, J., Geng, Z., Qi, S., Du, L., Hu, Q., Cai, M., et al. (2026). Characterization of the Anti-Alzheimer Drug Lecanemab by Mass Spectrometry. ACS Omega. https://doi.org/10.1021/acsomega.6c02666
Vancouver
Sha J, Geng Z, Qi S, Du L, Hu Q, Cai M, et al. Characterization of the Anti-Alzheimer Drug Lecanemab by Mass Spectrometry. ACS Omega. 2026. doi:10.1021/acsomega.6c02666. PMID: 42368154.
BibTeX
@article{sha2026-42368154,
author = {Sha, Jiaojiao and Geng, Zijin and Qi, Shanyu and Du, Liangjia and Hu, Qianqian and Cai, Minqi and Chen, Dezhu and Chen, Yuehua and others},
title = {{Characterization of the Anti-Alzheimer Drug Lecanemab by Mass Spectrometry}},
journal = {ACS Omega},
year = {2026},
doi = {10.1021/acsomega.6c02666},
pmid = {42368154},
url = {https://doi.org/10.1021/acsomega.6c02666}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.